TFG ASSET MANAGEMENT GP LTD
Q2 2026 Form 13-F
GRAND CAYMAN, CAYMAN ISLANDS
CIK 0001515070
· CRD 156040
· SEC-registered investment adviser
Consolidated report · includes
3 managers
since Q2 2013
$635.1M Reported Value Total
TETRAGON PARTNERS L.P. reports 48 total accounts under management (AUM). There are 44 discretionary accounts valued at $6,401,701,093, and 4 non-discretionary accounts valued at $5.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
79 funds
· $15.0B gross asset value
Securitized Asset Fund: $9.5B · Private Equity Fund: $2.9B · Hedge Fund: $2.6B · Other: $35.6M
Source: Form ADV filed 2026-10-19
Reported value
$635.1M
Quarter over quarter
+4.5%
Holdings
32
Top-10 concentration
74.0%
Filing Structure
Reports holdings for
- TFG Asset Management L P · File #028-15282 · since Q2 2013
- TFG Asset Management US LP · File #028-15284 · since Q2 2013
- TFG Asset Management UK LLP · File #028-15285 · since Q2 2013
Key People
Form ADV owners & control persons
Sean Andrew Cote
GENERAL COUNSEL
Paul Ronald Gannon
CHIEF FINANCIAL OFFICER / CHIEF OPERATING OFFICER
Jessica Gold
CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 13, 2026 |
| Form | 13F-HR |
| Reported value | $635.1M |
| Positions | 32 |
| Change in reported value | +23.3% |
| New positions | 5 |
| Exited positions | 7 |
| Position turnover | 30.8% |
| Top-10 concentration | 74.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 13, 2026
|
32 | $635.1M |
|
Q1 2026 13F
Filed May 15, 2026
|
34 | $515.1M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
28 | $474.3M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
36 | $747.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $620.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
25 | $438.2M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
19 | $391.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
16 | $354.5M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
18 | $400.9M |
|
Q1 2024 13F
Filed May 15, 2024
|
18 | $441.5M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
21 | $415.3M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
28 | $548.3M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
31 | $740.6M |
|
Q1 2023 13F
Filed May 15, 2023
|
32 | $747.5M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
47 | $697.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
122 | $829.7M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
154 | $1.5B |
|
Q1 2022 13F
Filed May 16, 2022
|
168 | $2.2B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
160 | $1.7B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
158 | $1.6B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PATH UIPATH INC | $336.4M | 52.98% |
| 2 | KGEI KOLIBRI GLOBAL ENERGY INC | $33.8M | 5.33% |
| 3 | AUTL AUTOLUS THERAPEUTICS LTD | $15.2M | 2.39% |
| 4 | LYFT LYFT INC | $14.6M | 2.3% |
| 5 | DFTX DEFINIUM THERAPEUTICS INC | $13.5M | 2.13% |
| 6 | WK WORKIVA INC | $12.1M | 1.91% |
| 7 | CXM SPRINKLR INC | $11.4M | 1.79% |
| 8 | MBX MBX BIOSCIENCES INC | $11.2M | 1.77% |
| 9 | ALKT ALKAMI TECHNOLOGY INC | $10.9M | 1.71% |
| 10 | CLDX CELLDEX THERAPEUTICS INC NEW | $10.8M | 1.7% |
| 11 | RLAY RELAY THERAPEUTICS INC | $10.7M | 1.68% |
| 12 | ARWR ARROWHEAD PHARMACEUTICALS IN | $10.6M | 1.67% |
| 13 | PHVS PHARVARIS N V | $10.2M | 1.61% |
| 14 | ALKS ALKERMES PLC | $10.0M | 1.57% |
| 15 | IMVT IMMUNOVANT INC | $9.9M | 1.55% |
| 16 | AXSM C AXSOME THERAPEUTICS INC. | $8.6M | 1.35% |
| 17 | SLN SILENCE THERAPEUTICS PLC | $8.4M | 1.32% |
| 18 | DYN DYNE THERAPEUTICS INC | $7.9M | 1.25% |
| 19 | IONS IONIS PHARMACEUTICALS INC | $7.7M | 1.21% |
| 20 | AGIO AGIOS PHARMACEUTICALS INC | $7.6M | 1.2% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.